Abstract #1394569: Efficacy and Safety of Empagliflozin: Real-World Tertiary Center Experience from the Kingdom of Saudi Arabia

Abstract

1. To determine the efficacy and safety of using Empagliflozin in the Saudi population, which was less well represented in randomized controlled trials. 2. Is the genitourinary infection risk any different in our population, where most males undergo circumcision at an early age and have water-based hygiene methods? 3. Can fasting during Ramadan impact the risk of dehydration, ketoacidosis, hypoglycemia, and hospitalization? We retrospectively reviewed case records of 637 patients treated with Empagliflozin. We show 0.42% improvement in glycated hemoglobin, 4.2 % weight loss, and cardiorenal efficacy and safety, as indicated by improvement in left ventricular ejection fraction and reduction in albuminuria when using Empagliflozin. Our patients did not observe an increased risk of genitourinary infections, hypoglycemia, dehydration, or hospitalizations. Empagliflozin was tolerated well during Ramadan with no increased incidence of adverse events. We postulate that glycosuria induced by Empagliflozin is not the sole contributor to the increased risk of genitourinary infections. Factors such as local hygiene and circumcision might impact this risk. Fasting does not increase the risk of adverse events.